Insights

Strategic Funding Dyne Therapeutics has secured substantial funding amounting to $326 million, indicating strong financial backing and potential for growth, making them an attractive target for partnerships or investments.

Innovative Product Pipeline Dyne Therapeutics boasts a diverse pipeline of therapeutics for serious muscle diseases, including ongoing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Their focus on developing life-transforming treatments presents collaboration opportunities for organizations seeking cutting-edge solutions in the biotechnology sector.

Leadership Transition With the recent appointment of John Cox as the CEO, Dyne Therapeutics is under new leadership known for their industry experience and strategic vision. This transition could signal a fresh direction or approach, opening doors for discussions around new partnerships or business opportunities with the company.

Clinical Trial Success The successful clinical data releases from the ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD showcase Dyne Therapeutics' efficacy in impacting disease biomarkers and functional endpoints. This positive outcome can be leveraged to engage potential collaborators or clients looking for evidence-backed solutions in the biotech research field.

Investor Interest Renowned investment firms like Renaissance Technologies LLC and Commodore Capital LP have recently shown interest in Dyne Therapeutics with multi-million dollar investments. This investor confidence could be an indicator of the company's market potential, making them an appealing target for strategic alliances or commercial partnerships.

Similar companies to Dyne Therapeutics

Dyne Therapeutics Tech Stack

Dyne Therapeutics uses 8 technology products and services including Akamai, Jupyter, Popper, and more. Explore Dyne Therapeutics's tech stack below.

Akamai
Content Delivery Network
Jupyter
File Sharing
Popper
Miscellaneous
Microsoft
Miscellaneous
Module Federation
Miscellaneous
Yoast SEO
Search Engines
HSTS
Security
Acquia Cloud Site Factory
Web Hosting

Media & News

Dyne Therapeutics's Email Address Formats

Dyne Therapeutics uses at least 1 format(s):

Dyne Therapeutics Email Formats	Example	Percentage
FLast@dyne-tx.com	JDoe@dyne-tx.com	94%
First.Last@dyne-tx.com	John.Doe@dyne-tx.com	5%
Last@dyne-tx.com	Doe@dyne-tx.com	1%

Frequently Asked Questions

Where is Dyne Therapeutics's headquarters located?

Dyne Therapeutics's main headquarters is located at 1560 Trapelo Rd Waltham, Massachusetts 02451 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Dyne Therapeutics's phone number?

You can contact Dyne Therapeutics's main corporate office by phone at

+1-857-201-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Dyne Therapeutics's stock symbol?

Dyne Therapeutics is a publicly traded company; the company's stock symbol is DYN.

What is Dyne Therapeutics's official website and social media links?

Dyne Therapeutics's official website is dyne-tx.com and has social profiles on LinkedIn.

How much revenue does Dyne Therapeutics generate?

As of September 2024, Dyne Therapeutics's annual revenue reached $35M.

What is Dyne Therapeutics's SIC code NAICS code?

Dyne Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Dyne Therapeutics have currently?

As of September 2024, Dyne Therapeutics has approximately 177 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: J. C.Chief Medical Affairs Officer: A. D.Chief Scientific Officer: O. B.. Explore Dyne Therapeutics's employee directory with LeadIQ.

What industry does Dyne Therapeutics belong to?

Dyne Therapeutics operates in the Biotechnology Research industry.

What technology does Dyne Therapeutics use?

Dyne Therapeutics's tech stack includes AkamaiJupyterPopperMicrosoftModule FederationYoast SEOHSTSAcquia Cloud Site Factory.

What is Dyne Therapeutics's email format?

Dyne Therapeutics's email format typically follows the pattern of . Find more Dyne Therapeutics email formats with LeadIQ.

How much funding has Dyne Therapeutics raised to date?

As of September 2024, Dyne Therapeutics has raised $326M in funding. The last funding round occurred on May 21, 2024 for $326M.

When was Dyne Therapeutics founded?

Dyne Therapeutics was founded in 2018.

Dyne Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com. 

To view our community guidelines, click here: https://bit.ly/3BYPnpK

Company Overview

Headquarters: 1560 Trapelo Rd Waltham, Massachusetts 02451 US
Phone number: ✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-857-201-****
Website: dyne-tx.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: DYN
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2018
Employees: 51-200

Media & News

Funding & Financials

$326M
Dyne Therapeutics has raised a total of $326M of funding over 6 rounds. Their latest funding round was raised on May 21, 2024 in the amount of $326M.
$10M$50M
Dyne Therapeutics's revenue is in the range of $10M$50M

Funding & Financials

$326M
Dyne Therapeutics has raised a total of $326M of funding over 6 rounds. Their latest funding round was raised on May 21, 2024 in the amount of $326M.
$10M$50M
Dyne Therapeutics's revenue is in the range of $10M$50M

Company Leadership

J. C.
Chief Executive Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. D.
Chief Medical Affairs Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
O. B.
Chief Scientific Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. N.
Chief Technical Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. H.
Chief Operating Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

D. B. F.
Chief Regulatory Affairs Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. M.
Chief Business Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
K. C.
Executive Assistant To Chief Scientific Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
W. F.
Chief Medical Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. T.
Vp, Head Of Technology
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Dyne Therapeutics

Sarepta Therapeutics

PepGen

Vertex Pharmaceuticals

Beam Therapeutics

ProQR Therapeutics

Rheos Medicines

Generation Bio

Dynacure

Dyno Therapeutics

Prevail Therapeutics

Stoke Therapeutics

Affinia Therapeutics

Dyne Therapeutics Tech Stack

Media & News

Renfund invests into Dyne Tx $4.45M.

Dyne Tx has issues with possible securities related infractions.

Joshua Brumm left Dyne Tx as president and CEO on Mar 1st '24.

Commodorecapital invests into Dyne Tx $12M.

Dyne Tx launches clinical data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD.

Dyne Tx hired John Cox as CEO on Mar 25th '24.

Dyne Tx launched Q4 earnings report on Mar 5th '24.

Dyne Therapeutics's Email Address Formats

Frequently Asked Questions

Where is Dyne Therapeutics's headquarters located?

What is Dyne Therapeutics's phone number?

What is Dyne Therapeutics's stock symbol?

What is Dyne Therapeutics's official website and social media links?

How much revenue does Dyne Therapeutics generate?

What is Dyne Therapeutics's SIC code NAICS code?

How many employees does Dyne Therapeutics have currently?

What industry does Dyne Therapeutics belong to?

What technology does Dyne Therapeutics use?

What is Dyne Therapeutics's email format?

How much funding has Dyne Therapeutics raised to date?

When was Dyne Therapeutics founded?

Dyne Therapeutics

Company Overview

Media & News

Renfund invests into Dyne Tx $4.45M.

Dyne Tx has issues with possible securities related infractions.

Joshua Brumm left Dyne Tx as president and CEO on Mar 1st '24.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?